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http://dx.doi.org/10.1016/j.fjs.2012.Summary Objective: To investigate the role of postoperative chemoradiotherapy in locally
advanced esophageal cancer after primary surgery.
Methods: Forty-one patients with locally advanced esophageal cancer (30/41 pathologic Stage
IIIA-C, 73.2%) who underwent radical surgery and complete postoperative chemoradiotherapy
between May 2004 and May 2010 were enrolled. The radiotherapy was delivered by the
intensity-modulated radiotherapy technique. Concurrently, chemotherapy with cisplatin and
5-fluorouracil was given on the 1st week and the 5th week of radiotherapy. The overall survival,
disease-free survival, and local recurrence rate were calculated to determine the role of post-
operative radiotherapy in locally advanced esophageal cancer. Univariate analysis was used to
elucidate the prognostic risk factors.
Results: After a median follow-up of 34.5 months (range, 3e87 months), the median overall
survival was 13 months. The 1-year and 3-year overall survival rates were 61.0 % and 24.6%,
respectively. The disease free survival after 1 year and 3 year was 42.8% and 28.1%, respec-
tively. There was a significant difference in survival between the patients who had N0/1 and
N2/3 disease by univariate analysis with 1-year survival and median survival rates of 66.7%
versus 37.5% and 17 months versus 10.5 months, respectively (pZ 0.036). The local recurrence
rate was 17.1 % (7/41) at 3 years. Acute treatment-related toxicities were mild. Most of the
patients died of distant metastasis.of Chest Surgery, Taichung Veterans General Hospital, No. 160, Sec. 3, Chung-Kang Road, Taichung
(C.-P. Hsu).
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Postoperative chemoradiotherapy for esophageal cancer 173Conclusion: Postoperative chemoradiotherapy showed a mild acute treatment-related toxicity
and a relatively good local control but these effects did not contribute a higher survival rate to
patients with advanced esophageal cancer.
Copyright ª 2012, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Esophageal cancer is a notorious, insidious disease because
over 50e60% of patients are diagnosed at the advanced,
unresectable stage, and the 5-year overall survival rate
improved only a little from 5% in the years 1975e1977 to
19% in 1999e2005.1 Since the prognosis is grave for the
advanced stage of esophageal cancer, a single treatment
mode such as surgery alone is reserved for early stage
tumors only.2 The 3-year overall survival rate in squamous
cell carcinoma treated by surgery alone is 6e35%.2 Post-
operative radiotherapy was shown to improve mostly local
control and a few studies also reported that this modality
improved both local control and survival in thoracic
esophageal squamous cell carcinoma.3,4 Distant metastasis
accounts for most failures after surgical treatment as it
occurs in over 60% of the patients with locally advanced
esophageal cancer. Based on the recent clinical data,
postoperative adjuvant therapy is a reasonable approach
for the treatment of locally advanced esophageal cancer
with or without positive regional lymph nodes after
surgery.5 Postoperative chemoradiotherapy is now a stan-
dard treatment in the USA for patients with a node-positive
adenocarcinoma of the stomach or gastroesophageal junc-
tion according to the results of the American intergroup
trials.6 However, the optimum postoperative adjuvant
therapy for esophageal cancer, especially for squamous cell
carcinoma of the thoracic esophagus has not yet been
established.
In our hospital, the treatment guideline for patients with
T1e2N0M0 tumors (according to the 2010 AJCC staging
system) is to perform surgery. Palliative treatment or best
supportive care is given to those who already have distant
metastasis on presentation. Patients with a T3e4N1e3M0
tumor are usually treated using one of our neoadjuvant
chemoradiotherapy treatment protocols in our treatment
guidelines. However, some patients who had clinically
staged T1e2N0M0 were found to have unsuspected T3e4 or
N1e3 disease during surgery. Some technically resectable
but locally advanced esophageal cancers were also treated
by surgery initially. For patients with a pathologic stage
T3e4N0M0 tumor, our treatment guidelines suggest an
additive of postoperative radiotherapy because of the
benefit of local control. For a patient with a pathologically
stage T3e4N1e3 tumor, our treatment guidelines suggest
an addition of postoperative chemoradiotherapy 4e6 weeks
after the operation in an attempt to improve overall
survival. If the patient refuses chemotherapy, our recom-
mended adjuvant therapy is postoperative radiotherapy.
Some studies have shown survival benefits from post-
operative adjuvant chemoradiotherapy for patients with
locally advanced stage of disease, especially for tumorslocated at the lower thoracic esophagus or esophagogastric
junction. This retrospective study was conducted to inves-
tigate the treatment outcomes of the patients who had
technically resectable but locally advanced squamous cell
carcinoma or unsuspected T3e4 or N1e3 squamous cell
carcinoma discovered during surgery. These patients have
subsequently been treated by postoperative chemo-
radiotherapy in our hospital since 2004.
2. Materials and methods
2.1. Patient population, surgery and adjuvant
chemotherapy
Between May 2004 and May 2010, 715 patients with
esophageal cancer were admitted to our hospital for
treatment. Surgery alone was performed for 10% of the
patients; about 40% of the patients with locally advanced
stage of esophageal cancer received definitive chemo-
radiotherapy, while palliative treatment was reserved for
patients with Stage IV disease. The remaining patients
received postoperative radiotherapy, postoperative
chemoradiotherpy or neoadjuvant chemoradiotherapy
(since 2007). In this study, we enrolled 41 patients who had
technically resectable but locally advanced thoracic
esophageal cancer or unsuspected T3e4 or N1e3 thoracic
esophageal cancer discovered in surgery and who under-
went complete postoperative chemoradiotherapy. Those
patients who did not complete postoperative chemo-
radiotherapy were excluded from this study. Esoph-
agectomy was performed through a three-phase incision
with extensive two-field lymph node dissection in the
mediastinum and abdomen. The stomach was mobilized to
the neck via the retrosternal route and a cervical esopha-
geal anastomosis was performed. Most patients in this study
were males with a mean age of 54 years (range, 34e78
years) and a male-to-female ratio of 40:1. The pathological
stages of these patients were assigned according to the
recommendation of the American Joint Committee on
Cancer’s tumorelymph nodeemetastasis classification.7
Patient characteristics and tumor stages are shown in
Table 1. Over 73% (30/41) of the patients were Stage IIIA-C
by pathological staging (Table 1).
2.2. Chemotherapy
Adjuvant chemotherapy was carried out concurrently with
radiotherapy. This consisted of two cycles of cisplatin and
5-fluorouracil (5-FU). Cisplatin was administered at a dose
of 20 mg/m2/day i.v. within 60 minutes after adequate
hydration for 4 days and 5-FU was administered via
Table 1 Characteristics of patients.
Variables n (%)
Age (37e78 y)
<55 y 22 (53.7)
55 y 19 (46.3)
Sex
Female 1 (2.4)
Male 40 (97.6)
Stage
pII 11 (26.8)
pIIA 6 (14.6)
pIIB 5 (12.2)
pIII 30 (73.2)
pIIIA 17 (41.5)
pIIIB 3 (7.3)
pIIIC 10 (24.4)
pT
T2 4 (9.8)
T3 27 (65.9)
T4a 10 (24.4)
pN
N0 11 (26.8)
N1 22 (53.7)
N2 4 (9.8)
N3 4 (9.8)
Size
<5 cm 15 (37.2)
5 cm 26 (67.4)
Tumor grade
1 0 (0)
2 13 (31.7)
3 28 (68.3)
Histologic type 41 (100)
Squamous cell carcinoma
174 H.-L. Yeh et al.continuous infusion of 800 mg/m2/day for 4 days in the 1st
week and 5th week of radiotherapy. For 26 of 41 patients,
two to four more adjuvant chemotherapy cycles with the
same regimen were added through recommendation of the
surgeons to intensify the adjuvant therapy.
2.3. Radiotherapy
Radiotherapy was administered 4e6 weeks postoperatively
using an intensity-modulated radiation therapy (IMRT)
treatment plan. All patients underwent computed tomog-
raphy (CT) simulation in a supine position with their arms
above their heads, and a customized vacuum bag was used
for immobilization. The CT images were taken at a 5-mm
thickness throughout the neck and the entire thorax for the
upper and the middle thoracic tumors or the entire thorax
and the abdomen for the lower thoracic tumors. Since the
tumor was resected along with the esophagus during the
operation, the gross tumor volume was not assessed. Clin-
ical tumor volume (CTV), planning tumor volume (PTV), and
the organs at risk were outlined on the CT images. CTV
included the whole esophageal region, lymph nodes in the
mediastinum and supraclavicular area (if the tumor was
located in the upper or middle thoracic portion), and celiactrunk region (if the tumor was located in the lower thoracic
portion). A margin of 0.5 cm was also added to the CTV as
PTV to allow for the daily setup error and organ motion.
The IMRT plan was delivered to each patient by a linear
accelerator (Varian 2100EX with a 120-leaf Millennium
multileaf collimator; Varian Oncology Systems, Palo Alto,
CA, USA) using 6 MV photons. Dose calculations were
performed using the Varian Eclipse planning system
(versions 6.5e7.2.24) based on the pencil beam model. A
total dose of 45e50.4 Gy in 25e28 fractions within 5e6
weeks was administered to the PTV. For both lungs, the
dose limit to the mean dose was set at 16 Gy, and the
volume receiving more than 20 Gy (V20) was limited to 30%.
For the heart, as another organ at risk, the dose was set at
the volume receiving 35 Gy less than a volume of 30%. For
the spinal cord the maximum dose was set at 40 Gy. Six or
seven beam portals were used to deliver the required doses
to the targets. The beam direction was determined care-
fully according to the shape of CTV to reduce the possibility
of normal lung tissue receiving more than the prescribed
doses. The quality of the plan was evaluated by dose
volume histogram, dose distribution curves, and a calcu-
lated conformity index.
2.4. Toxicity assessment
Acute toxicities such as radiation pneumonitis and hema-
tologic toxicity (leukopenia, anemia, and thrombocyto-
penia) were evaluated each week during the treatment and
every 2 weeks after radiotherapy for 3 months. All
treatment-related toxicities were assessed according to the
toxicity criteria of the Radiation Therapy Oncology Group
(RTOG).8
2.5. Follow-up evaluation
Follow-up evaluations were performed every 2 weeks after
radiotherapy for the first 3 months and then every month
for 2 years. The diagnosis for recurrence or metastasis was
aided by clinical examinations including physical examina-
tion, CT, esophagoscopy plus biopsy, and/or positron
emission tomography scan. Survival analysis by the
KaplaneMeier Method was performed using SPSS statistical
software. Differences were considered significant if the
two-tailed p value was less than 0.05.
3. Results
3.1. Clinical results
After a median follow-up of 34.5 months (range, 15e94
months), the median overall survival was 13 months. The 1-
year and 3-year overall survival rates were 61.0% and 24.6%,
respectively (Fig. 1). The disease-free survival rates at 1
year and 3 years were 42.8% and 28.1%, respectively. There
was a significant difference in survival between the
patients who had N0/1 disease and those having N2/3
disease by univariate analysis with 1-year survival and
median survival rates of 66.7% versus 37.5% and 17 months
versus 10.5 months, respectively (p Z 0.036; Fig. 2).
Figure 1 Overall survival (n Z 41 patients).
Table 2 Chemoradiotherapy toxicity (n Z 41).
n (%)
Nausea, vomiting ( Grade 3) 1 (2.4)
Mucositis, dysphagia ( Grade 3) 4 (9.8)
Neutropenia (<109/L) 9 (22.0)
Lung toxicity ( Grade 3) 0 (0)
Cardiac toxicity ( Grade 3) 1 (2.4)
Toxic death 0 (0)
Postoperative chemoradiotherapy for esophageal cancer 175The local recurrence rate was 17.1% (7/41) at 3 years. In
seven patients who had local recurrence, three had tumor
local recurrence at the anastomotic site, which was
discovered by a CT scan first, and proved by an endoscopic
biopsy. The other four had recurrence at the tumor bed,
which was detected by the abnormal soft tissue mass found
by a CT scan of the chest only. Most deaths during follow-up
were due to distant metastases. There were five patients
who showed distant metastasis to the lungs only during
follow-up; two patients had distant metastasis to the liver
only; one patient had brain metastasis; most patients with
distant metastasis showed multiple sites of distant metas-
tases. The percentage of patients with distant metastasis
was 58.5% (24/41). Acute toxicity during treatment was
mild with 9 of 41 patients exhibiting Grade 3 leukopenia
and none had Grade 3 or above lung toxicity (Table 2). Six
patients needed periodic esophageal balloon dilatation for
the stenosed anastomosis shortly after the operation,
which was not considered a side effect of postoperative
chemoradiotherapy. Constrictive pericarditis was found in
one patient 4 months after postoperative chemo-
radiotherapy. That patient expired 2 months after the
appearance of the constrictive pericarditis in spite of
medical treatment. Another patient with pericardial effu-
sion, which occurred 3 months after postoperative che-
moradiotherapy was insufficiently controlled by
nonsteroidal anti-inflammatory drugs and he finally died of
local recurrence 12 months after the operation.Figure 2 Overall survival by pathologic N stage.3.2. Dosimetric results
In this study, six beam arrangement was used with beam
angles of 0, 60, 140, 155, 205, 305. One more beam
with beam angle 220 will be added if the PTV is mainly
situated at the central to right thoracic area to spare most
of the heart and lungs in the treatment fields. The dose
delivery was administrated smoothly in all cases. The dose
data for CTV and organs at risk are shown. PTV was not
taken into account in the calculation of the dose homoge-
neity index in this study as there is no standard volume for
contouring the postoperative esophageal region and the
PTV cover of the CTV in the supraclavicular region may be
too close to the skin, thus resulting in inhomogeneity
appearing at the skin surface. For the spinal cord, the
average maximum dose was 27.74 Gy, which is relatively
low for the spinal cord. The mean dose for the lungs was
13.19 Gy. The average volume receiving radiation doses
more than 5 Gy (V5) and V20 for the lungs was 70.9% and 22%
respectively, which is lower than the dose limit known to
increase the risk of radiation pneumonitis.9 A typical
isodose distribution of IMRT plan is presented in Fig. 3.
The average treatment time was around 15 minutes for
each plan.
4. Discussion
Based on historical studies, the primary treatment of
esophageal cancer is either surgical or nonsurgical. Surgery
is the standard treatment for early stage esophageal
cancer, although only 30e40% of patients have potentially
operable disease at presentation. For patients with inop-
erable esophageal cancer, or who have a complicated
medical problem, and are therefore not suitable to undergo
an operation, the combined modality therapy using both
chemotherapy and radiotherapy concurrently was recorded
in many nonrandomized and randomized clinical studies in
the past. Among these previous studies, the RTOG 85-01
trial reported by Herskovic et al showed the superiority of
chemoradiotherapy over radiation therapy alone.10 The
patients in the chemoradiotherapy arm received radio-
therapy (50 Gy in 25 fractions) and two cycles of intrave-
nous infusion of cisplatin (75 mg/m2 on Day 1) and 5-FU
(1000 mg/m2 every 24 hours for 4 days) on the 1st and 5th
weeks of radiotherapy and then every 3 weeks for two more
cycles after radiotherapy. The control arm received radia-
tion therapy alone with higher radiation doses (64 Gy) than
the chemoradiotherapy arm. The 5-year overall survival
rate (27% vs. 0%, p < 0.0001) and the median survival rate
(14 months vs. 9 months) were significantly improved in the
Figure 3 A typical isodose distribution of an intensity-modulated radiation therapy plan.
176 H.-L. Yeh et al.chemoradiotherapy arm. Based on the positive results from
the RTOG 85-01, the conventional nonsurgical treatment
for esophageal cancer is now chemoradiotherapy.
Patients who are found to have advanced esophageal
cancer after primary surgery may need adjuvant therapy.
Distant metastasis is the most important factor for the
treatment failure in advanced esophageal cancer. In order
to cope with distant metastasis, systemic therapy such as
chemotherapy is a reasonable adjuvant therapy for
advanced esophageal cancer. A nonrandomized Phase II
study5 in 2003 in a single institute compared the result of
postoperative chemoradiotherapy in 31 patients with
advanced esophageal cancer (26 cases of ademocarcinoma
and 5 cases of squamous cell carcinoma) and esoph-
agectomy alone in 52 patients (43 cases of adenocarcinoma
and 9 cases of squamous cell carcinoma) in 2003. Chemo-
therapy was given by two 4-day cycles of intravenous infu-
sion of cisplatin (20 mg/m2/day) and 5-FU (1000 mg/m2/
day) in the 1st and 4th weeks of adjuvant therapy in patients
who received postoperative chemoradiotherapy. Radio-
therapy with 50.4e59.4 Gy in 1.8 daily fractions was given
to the tumor bed. The addition of postoperative chemo-
radiotherapy to esophagectomy in patients who had locally
advanced esophageal cancer doubled the survival time,
time to recurrence, and recurrence-free survival.5
However, in a prospective randomized study of post-
operative chemotherapy versus chemoradiotherapy re-
ported, Tachibana et al expressed an opposing opinion.11
Forty-five patients with advanced squamous cell carci-
noma of the esophagus were randomized to receive either
postoperative chemotherapy or postoperative chemo-
radiotherapy. The chemotherapeutic regimen was the same
in both groups, and cisplatin (50 mg/m2) was given by
intravenous infusion on Days 1 and 15, and the 5-FU
(300 mg/m2) was given daily by continuous intravenous
infusion for 5 weeks. In the postoperative chemo-
radiotherapy group, 50 Gy of radiotherapy was given to the
mediastinum over 5 weeks. There was no improvement
in the survival rate by adding radiotherapy to posto-
perative chemotherapy.11 Whether postoperative chemo-
radiotherapy has survival benefits for the patients who arefound to have advanced-stage esophageal cancer during the
operation is a controversial issue.
In our retrospective study, the role of adjuvant chemo-
radiotherapy in advanced esophageal squamous cell carci-
noma after primary surgery was assessed. The median
overall survival was 13 months with a projected 3-year
overall survival of 24.6%. Most of the patients who were
entered into this study had a pathologic Stage IIIA-C tumor
(73.2%), and only six (14.6%) patients had Stage IIA esoph-
ageal cancer. Therefore a poor prognosis would be ex-
pected. Our results are inferior to the 3-year projected
overall survival of 27% and the freedom-from-recurrence
rate of 31% reported in a study of multimodality therapy at
the Cleveland Clinic.12 However, the population in the
Cleveland study had a lower proportion of advanced stage
(50% of Stage III or above) cancer and so it may not be
meaningful to compare the results with ours. The local
recurrence rate in the current study was 17.1%, which is
better than the local-regional failure rates reported in the
surgical arms of recent randomized trials.13 The local-
regional failure sites in the current study were found
within the treatment field in three cases, and in the other
four cases local recurrence was found at the anastomostic
site. Further research is needed to improve the local
control by augmented the radiation doses.
Univariate analysis shows a significant difference in
survival between the patients who had no lymph node
involvement (N0) or only one or two lymph node metastases
(N1) and patients who had metastases to more than two
lymph nodes (N2/N3). The 1-year survival and median
survival rate for N0/N1 and N2/N3 were 66.7% versus 37.5%
and 17 months versus 10.5 months, respectively
(p Z 0.036). There were no significant differences in
survival based on age, T stage, tumor grade, tumor sites,
angiolymphatic invasion, or perineural invasion by univar-
iate analysis. The number of lymph nodes involved in
metastases found in the pathologic specimen played an
important role in the prediction of prognosis. This result
reconfirmed our previous assertion from demonstrating the
prognostic importance of the extent of nodal involvement
in squamous cell carcinoma of the thoracic esophagus.14
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surgery alone in resectable adenocarcinoma at the gastro-
esophageal junction in a retrospective study with 211
patients, also showing that the positive node status in the
resected specimen had a significant partial effect on
survival.15 The combined modalities for the detection of
lymph node involvement during clinical staging by endo-
scopic ultrasonography, a CT scan of the chest and
abdomen and a 2-fluoro-2-deoxy-D-glucose positron emis-
sion tomographic scan, should be used.
Pulmonary toxicity is a challenging issue in the radiation
therapy of esophageal cancer with or without chemo-
therapy in a postoperative setting. By using IMRT, we can
reduce the doses to the lungs as low as possible without
compromising the total doses to the treatment target
(esophageal bed). In this study, our mean V20 and V5 were
20% and 70.9%, respectively, both lower than those in the
RTOG criteria for minimizing the risk of radiation pneumo-
nitis. None of our patients suffered from Grade 3 or above
radiation pulmonary toxicity during the postoperative
chemoradiotherapy. A reported correlation between V20
and severity of radiation pneumonitis showed 0% of radia-
tion pneumonitis when V20 was controlled below 22%, and
the risk increased to more than 19% when V20 was more
than 40%.9 Our results agree with those in that report, and
a further large-scale study to confirm the role of V20 in the
relationship to the risk of radiation pneumonitis in thoracic
radiation therapy is suggested.
For patients who are found to have node-positive disease
during the operation, adjuvant therapy is a reasonable
approach to improve clinical outcomes. Macdonald et al
conducted a large randomized intergroup trial of post-
operative chemoradiotherapy for patients with adenocar-
cinoma in the stomach and at the esophagogastric junction
in 2001. The 3-year overall survival rate was 41% in patients
who had surgery alone as compared with 50% in patients
who had both surgery and postoperative chemo-
radiotherapy.6 Postoperative chemoradiotherapy is now
a standard approach in the USA for patients who have node-
positive adenocarcinoma of the stomach or gastroesopha-
geal junction. For patients who had primary advanced
squamous cell carcinoma of the esophagus, some retro-
spective studies suggested a potential benefit in survival
after postoperative chemoradiotherapy. A mature Phase II
clinical trial reported by the Cleveland Clinic in 2009 sup-
ported the benefit in survival from postoperative chemo-
radiotherapy in poor-prognosis cancer of the esophagus and
gastroesophageal junction.16 However, data from Japan did
not demonstrate any survival benefit by adding radio-
therapy to chemotherapy in adjuvant setting.11 To date, no
large randomized clinical trials have shown that the use of
postoperative chemoradiotherapy in advanced esophageal
cancer as compared with surgery alone improves survival,
and thus the therapeutic benefit remains unclear.
5. Conclusions
Multimodality treatment in advanced esophageal cancer is
attractive theoretically but the optimal mode of treatment
has not yet been established. Our study showed a relatively
good local control of the disease by the addition ofpostoperative chemoradiotherapy to locally advanced
esophageal squamous cell carcinoma with a mild, acute
treatment-related toxicity, but this did not contribute
a higher survival rate for this group of patients.References
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